Ascites Market: Information by Types (Transudative Ascites and Exudate Ascites), Diagnosis (Ultrasound, CT Scan, Laparoscopy and Angiography), Treatment (Surgeries), End Users (Hospitals & Clinics, Ambulatory Surgical Center and Diagnostic Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

The Ascites Market is expected to register a CAGR of 4.0%and is anticipated to reach USD 2,832.5 million by 2023. Ascites is an abnormal accumulation fluid in the abdominal cavity. Liver cirrhosis is the most common cause of ascites. Its presence is a sign of significant portal hypertension. Other less common factors that may contribute to ascites development are heart failure, kidney failure, cancers, and infection in pancreas. Malignant ascites has a characteristic role in the progression of ovarian cancer. Malignancy-related ascites have also been observed in malignancies of breast, lung, pancreas, gastric, and liver. Ascites can be detected by physical examination at a volume higher than 1.5 l ascites. For a smaller amount of fluid ultrasound, and CT scan are preferred

The rising prevalence of cirrhosis, improvement in reimbursement policies, and increasing occurrence of cancer are the major drivers propelling market growth. However, the complications associated with the ascites treatment constrain the growth of the market.

Market Dynamics

The rising prevalence of cirrhosis is expected to drive the growth of the market. For instance, according to a study published in the Canadian Journal of Gastroenterology and Hepatology in 2016, Cirrhotic ascites accounts for more than 75% of patients who are admitted to hospital with ascites. Moreover, liver cirrhosis is also found to be prevalent in the European region. Owing to the increasing alcohol consumption and obesity, liver cirrhosis is the third most common cause of premature mortality in the UK as compared to other countries in Western Europe, suggested by a study published in BMJ Open in 2017. Ascites is the most common complication of cirrhosis that leads to hospitalization and use of healthcare resources, thus increasing the prevalence of cirrhosis is expected to propel the ascites market during the forecast period.

Ascites Market Size, by End User, 2016 (USD Million)  

  Source: MRFR Analysis

Segmentation

The ascites market has been segmented into types, diagnosis, treatment, and end-users. By types, the market has been segmented into transudative ascites and exudate ascites. Based on the diagnosis, the market has been segmented into ultrasound, CT scan, laparoscopy, and angiography. By treatment, the market has been segmented into surgeries. On the basis of end-users, the market has been segmented into hospitals & clinics, ambulatory surgical center, and diagnostic centers. The hospitals & clinics segment accounted for a market value of USD 838.4 million in 2016.

Key Players

The prominent players in the ascites market are Sequana Medical NV (Switzerland), BioVie Inc. (US), PharmaCyte Biotech Inc. (US), Fresenius SE & Co. KGaA (Germany), BD (US), GI Supply (US), and Medtronic (Ireland).

Some of the key strategies followed by the players operating in the ascites market were innovation, product development, acquisition, and expansion.

Asia-Pacific Ascites Market Share, by Country, 2016 (%)  

Source: MRFR Analysis

Regional Analysis

The ascites market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounts for the significant share of the market owing to the improvement in reimbursement policies, and high healthcare expenditure. Europe accounts for the second-largest market, which is followed by Asia-Pacific. Asia-Pacific is the fastest-growing ascites market due to the presence of enormous opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially in the African region.

Key Updates

• In December 2017, BioVie Inc. received FDA fast track designation for BIV201.

• In December 2017, Fresenius SE & Co. KGaA opened an extension of its production plant in Mihla, Germany by investing USD 11.78 million.

• In April 2017, BD acquired C R Bard Inc., for USD 24 billion to expand its portfolio of oncology and surgery segment.

Market Segmentation

Ascites Market, by Types

• Transudative Ascites


• Exudate Ascites

Ascites Market, by Diagnosis

• Ultrasound


• CT Scan


• Laparoscopy


• Angiography

Ascites Market, by Treatment

• Surgeries

Ascites Market, by End Users

• Introduction


• Hospitals & Clinics


• Ambulatory Surgical Center


• Diagnostic Centers

Ascites Market, by Region

• Americas




• North America




• US


• Canada




• South America




• Brazil


• Colombia


• Mexico


• Rest of South America

• Europe




• Western Europe




• Germany


• France


• UK


• Italy


• Spain


• Rest of Western Europe




• Eastern Europe

• Asia-Pacific




• China


• Japan


• India


• Australia


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• UAE


• Saudi Arabia


• Oman


• Kuwait


• Qatar


• Rest of Middle East


• Africa

Available Additional Customizations

• Additional Companies




• Sanofi Inc.


• TriOn Pharma


• General Electric


• Mylan NV




• Supply & Demand Analysis

Intended Audience

• Medical device manufacturers and distributors


• Government research organizations


• Hospitals and clinics


• Regulatory agencies


• Pharmaceutical companies